Compare drug alternatives
Invokamet ® Alternatives
Invokamet ®(Canagliflozin And Metformin Hydrochloride) | Glyxambi®(Empagliflozin And Linagliptin) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Oral. Learn more. | Oral . Learn more. |
Dosing | |
One tablet, twice daily with meals, recommended starting dose of canagliflozin is 50 mg twice daily and metformin HCl 500 mg twice daily. Learn more. | The recommended dose of GLYXAMBI is 10 mg empagliflozin and 5 mg linagliptin once daily, taken in the morning, with or without food. Dose may be increased to 25 mg empagliflozin and 5 mg linagliptin once daily.. Learn more. |
Latin Shorthand | |
1 tab BID with meals. Starting dose: canagliflozin 50 mg BID, metformin HCl 500 mg BID.. Learn more. | Recommended GLYXAMBI dose: 10mg empagliflozin + 5mg linagliptin qd in the AM, with or without food. May increase to 25mg empagliflozin + 5mg linagliptin qd.. Learn more. |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $10. Learn more. |
Annual Cap | |
$3,000 and $200 per month. Learn more. | $175 per month. Learn more. |
Assistance Expiration | |
Calendar year. Learn more. | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common adverse reactions associated with canagliflozin (5% or
greater incidence): female genital mycotic infections, urinary tract
infection, and increased urination.
Most common adverse reactions associated with metformin HCl (5% or
greater incidence) are diarrhea, nausea, vomiting, flatulence, asthenia,
indigestion, abdominal discomfort, and headache. . Learn more. | Most common adverse reactions (5% or greater incidence) were urinary tract
infections, nasopharyngitis, and upper respiratory tract infections.. Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | SGLT2 Inhibitors. Learn more. |
Special Populations | |